Art program highlights stories, lived experiences of people with SM
Blueprint medicines partnered with Twist Out Cancer to launch an art program that showcases what it’s like to live with systemic mastocytosis.
Blueprint medicines partnered with Twist Out Cancer to launch an art program that showcases what it’s like to live with systemic mastocytosis.
A recent study showed the standardization of screening and the use of diagnostic testing could improve ISM diagnosis rates.
In a recent study, 8% of patients with unexpected KIT mutations in myeloid neoplasms also met the diagnostic criteria for SM.
In a recent case report, a patient was wrongly diagnosed with carcinoid syndrome due to the similarity of her systemic mastocytosis symptoms.
In a recent study, researchers found distinct plasma protein profiles show potential to refine indolent and advanced SM diagnoses.
Researchers of a recently-published study found autoantibodies to type I [IFN] do not affect the pathogenesis or manifestations of SM.